scispace - formally typeset
C

Charles A. Dinarello

Researcher at University of Colorado Denver

Publications -  1073
Citations -  152254

Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.

Papers
More filters
Journal ArticleDOI

Ability of human leukocytic pyrogen to stimulate brain prostaglandin synthesis in vitro.

TL;DR: It is demonstrated that LP is a potent inducer of PGE synthesis in rabbit brain and that receptors for LP are not restricted to the thermoregulatory center, but rather may be distributed throughout the brain.
Journal ArticleDOI

Both Inflammatory and Endocrine Mediators Stimulate Host Responses to Sepsis

TL;DR: In this model hypermetabolism, hyperglycemia, hyper-insulinemia, insulin resistance, negative nitrogen balance, and accelerated protein flux were mediated predominantly by infusion of the counterregulatory hormones.
Journal ArticleDOI

Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury.

TL;DR: Exogenous administration of clinical grade AAT reduces caspase-1 activity in the ischemic myocardium leading to preservation of viableMyocardium and prevention of adverse cardiac remodeling.
Journal ArticleDOI

IL-32–dependent effects of IL-1β on endothelial cell functions

TL;DR: IL-32 is reported to be expressed and is also functional in human vascular endothelial cells (EC) of various origins, and the properties of this cytokine relevant to coagulation, endothelial inflammation, and atherosclerosis are introduced.
Journal ArticleDOI

IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease

TL;DR: The concept that IL-18 plays a major role in the pathogenesis of the autoimmune syndrome of lpr mice and that a reduction inIL-18 activity could be a therapeutic strategy in autoimmune diseases is supported.